138 related articles for article (PubMed ID: 16234588)
1. Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma.
Dvalishvili I; Charkviani L; Charkviani T; Turashvili G; Burkadze G
Georgian Med News; 2005 Sep; (126):27-31. PubMed ID: 16234588
[TBL] [Abstract][Full Text] [Related]
2. The expression of cadherin e and clinical prognostic factors in uterine endometrioid adenocarcinoma.
Dvalishvili I; Charkviani L; Turashvili G; Burkadze G
Georgian Med News; 2005 Nov; (128):17-21. PubMed ID: 16369055
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade.
Dvalishvili I; Charkviani L; Turashvili G; Burkadze G
Georgian Med News; 2006 Mar; (132):24-7. PubMed ID: 16636372
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
[TBL] [Abstract][Full Text] [Related]
5. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
7. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance.
Murray SK; Young RH; Scully RE
Int J Gynecol Pathol; 2003 Oct; 22(4):324-33. PubMed ID: 14501811
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
9. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumor aggressiveness.
Nazeer T; Church K; Amato C; Ambros RA; Rosano TG; Malfetano JH; Ross JS
Mod Pathol; 1994 May; 7(4):469-74. PubMed ID: 8066075
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium.
Stewart CJ; Crook ML; Lacey J; Louwen K
Int J Gynecol Pathol; 2011 Sep; 30(5):484-91. PubMed ID: 21804393
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer.
Alexander-Sefre F; Singh N; Ayhan A; Thomas JM; Jacobs IJ
Gynecol Oncol; 2004 Feb; 92(2):653-9. PubMed ID: 14766262
[TBL] [Abstract][Full Text] [Related]
12. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion.
Ismiil N; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Ackerman I; Thomas G; Covens A; Khalifa MA
Ann Diagn Pathol; 2007 Aug; 11(4):252-7. PubMed ID: 17630108
[TBL] [Abstract][Full Text] [Related]
13. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
Saygili U; Koyuncuoglu M; Altunyurt S; Guclu S; Uslu T; Erten O
Gynecol Oncol; 2001 Oct; 83(1):20-4. PubMed ID: 11585409
[TBL] [Abstract][Full Text] [Related]
14. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
Siami K; McCluggage WG; Ordonez NG; Euscher ED; Malpica A; Sneige N; Silva EG; Deavers MT
Am J Surg Pathol; 2007 Nov; 31(11):1759-63. PubMed ID: 18059234
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
Talvensaari-Mattila A; Santala M; Soini Y; Turpeenniemi-Hujanen T
Anticancer Res; 2005; 25(6B):4101-5. PubMed ID: 16309203
[TBL] [Abstract][Full Text] [Related]
16. Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma.
Stokes GN; Shelton JB; Zahn CM; Kendall BS
Gynecol Oncol; 2002 Jan; 84(1):58-61. PubMed ID: 11748977
[TBL] [Abstract][Full Text] [Related]
17. Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
Mylonas I; Mayr D; Walzel H; Shabani N; Dian D; Kuhn C; Kunze S; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):1975-80. PubMed ID: 17649808
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
Pozharisskiĭ KM; Samsonova EA; Ten VP; Maksimova NA; Urmancheeva AF
Arkh Patol; 2005; 67(2):13-7. PubMed ID: 15938112
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
20. Expression levels of adiponectin receptors are decreased in human endometrial adenocarcinoma tissues.
Yamauchi N; Takazawa Y; Maeda D; Hibiya T; Tanaka M; Iwabu M; Okada-Iwabu M; Yamauchi T; Kadowaki T; Fukayama M
Int J Gynecol Pathol; 2012 Jul; 31(4):352-7. PubMed ID: 22653349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
